AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14601338 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication package containing visual material
Number of subjects: 1890
Study 14601338 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (Control)
Number of subjects: 1890
Study 14601338 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication package
Number of subjects: 1890
Study 10783019 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive influenza A enzyme immunoassay (EIA) test
Number of subjects: 56
Study 10783019 — intervention group
Group type: COMPARATOR
Intervention: Negative influenza A enzyme immunoassay (EIA) test
Number of subjects: 56
Study 10783019 — intervention group
Group type: COMPARATOR
Intervention: No rapid diagnosis
Number of subjects: 56
Study 8793432 — intervention group
Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 120
Study 8793432 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 120
Study 1536441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (IPC group)
Number of subjects: 26
Study 1536441 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular buprenorphine (opioid group)
Number of subjects: 26
Study 6540222 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and droperidol
Number of subjects: 0
Study 31858963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 797
Study 31858963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 797
Study 31858963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (advanced to tofacitinib at month 3 or 6)
Number of subjects: 797
Study 30597768 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 16
Study 30597768 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 30382909 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 248
Study 30382909 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 248
Study 27495978 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention
Number of subjects: 116
Study 27495978 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based education
Number of subjects: 116
Study 24155184 — intervention group
Group type: EXPERIMENTAL
Intervention: Adlerian Parental Counseling (APC)
Number of subjects: 114
Study 24155184 — intervention group
Group type: COMPARATOR
Intervention: No intervention (non-APC group)
Number of subjects: 114
Study 22644005 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 88
Study 22644005 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 88
Study 20566677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 108
Study 20566677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 17387123 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based medication review by a pharmacist
Number of subjects: 136
Study 17387123 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 136
Study 16304312 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐TBB
Number of subjects: 293
Study 16304312 — intervention group
Group type: COMPARATOR
Intervention: TBB
Number of subjects: 293
Study 12528325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum milk preparation (42 g per day for 2 days preoperatively)
Number of subjects: 60
Study 12528325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9719976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anesthesia (STA)
Number of subjects: 66
Study 9719976 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA)
Number of subjects: 66
Study 9719976 — intervention group
Group type: EXPERIMENTAL
Intervention: Retro/peribulbar anesthesia (RBA)
Number of subjects: 66
Study 9719976 — intervention group
Group type: COMPARATOR
Intervention: All techniques (RBA, STA, TA)
Number of subjects: 66
Study 8124121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led programme using a family centred approach with follow up according to degree of risk
Number of subjects: 12472
Study 8124121 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 12472
Study 8124121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led programme
Number of subjects: 12472
Study 2527760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thymoxamine 40 mg
Number of subjects: 24
Study 2527760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thymoxamine 80 mg
Number of subjects: 24
Study 2527760 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study 202985 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine 200 mg daily for 3 weeks
Number of subjects: 23
Study 202985 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine 300 mg daily for 3 weeks
Number of subjects: 23
Study 202985 — intervention group
Group type: COMPARATOR
Intervention: Matching blanks (control)
Number of subjects: 23
Study 31733098 — intervention group
Group type: EXPERIMENTAL
Intervention: Liability to ADHD
Number of subjects: 0
Study 31733098 — intervention group
Group type: COMPARATOR
Intervention: Smoking initiation
Number of subjects: 0
Study 31262551 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face treatment (FtF)
Number of subjects: 73
Study 31262551 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat-based treatment
Number of subjects: 73
Study 31262551 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WL)
Number of subjects: 73
Study 28651927 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus evofosfamide (300 mg/m2 intravenously for 30-60 min on days 1 and 8 of every 21-day cycle for up to six cycles)
Number of subjects: 640
Study 28651927 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (75 mg/m2 via bolus injection or continuous intravenous infusion for 6-96 h on day 1 of every 21-day cycle for up to six cycles)
Number of subjects: 640
Study 28651927 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus evofosfamide
Number of subjects: 640
Study 28651927 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 640
Study 25465885 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training toward non-threat
Number of subjects: 0
Study 25465885 — intervention group
Group type: COMPARATOR
Intervention: Training toward threat
Number of subjects: 0
Study 25465885 — intervention group
Group type: COMPARATOR
Intervention: No-contingency condition
Number of subjects: 0
Study 23238034 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cups of coffee/day for 30 days
Number of subjects: 40
Study 23238034 — intervention group
Group type: COMPARATOR
Intervention: Coffee abstinence
Number of subjects: 40
Study 21814869 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper training plus brief behavioral rehearsal (role play practice)
Number of subjects: 147
Study 21814869 — intervention group
Group type: COMPARATOR
Intervention: Gatekeeper training as usual
Number of subjects: 147
Study 19344047 — intervention group
Group type: EXPERIMENTAL
Intervention: KADIAN q24h dosing
Number of subjects: 1428
Study 19344047 — intervention group
Group type: COMPARATOR
Intervention: KADIAN q12h dosing
Number of subjects: 1428
Study 19344047 — intervention group
Group type: EXPERIMENTAL
Intervention: KADIAN q12h dosing after switch
Number of subjects: 1428
Study 16731460 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 102
Study 16731460 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 102
Study 16731460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of hospitalization for heart failure or death
Number of subjects: 102
Study 16731460 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset AF in patients with baseline sinus rhythm
Number of subjects: 102
Study 15341360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraper
Number of subjects: 10
Study 15341360 — intervention group
Group type: COMPARATOR
Intervention: Soft-bristle toothbrush
Number of subjects: 10
Study 11144399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg once-daily
Number of subjects: 752
Study 11144399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg b.i.d.
Number of subjects: 752
Study 11144399 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/CA 13.3 mg/kg t.i.d.
Number of subjects: 752
Study 9134599 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy (120 mg in 50 mL saline, 5 x 10^7 viable organisms), weekly for 6 weeks after TUR
Number of subjects: 69
Study 9134599 — intervention group
Group type: COMPARATOR
Intervention: TUR alone (control)
Number of subjects: 69
Study 8362997 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 28
Study 8362997 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus incentives
Number of subjects: 28
Study 8362997 — intervention group
Group type: COMPARATOR
Intervention: Health risk assessment and risk factor education
Number of subjects: 28
Study 8362997 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 28
Study 3521523 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride‐hydrochlorothiazide
Number of subjects: 17
Study 3521523 — intervention group
Group type: COMPARATOR
Intervention: Triamterene‐hydrochlorothiazide
Number of subjects: 17
Study 31362537 — intervention group
Group type: EXPERIMENTAL
Intervention: MBB coaching (treatment)
Number of subjects: 195
Study 31362537 — intervention group
Group type: COMPARATOR
Intervention: Control (no coaching)
Number of subjects: 195
Study 29338723 — intervention group
Group type: EXPERIMENTAL
Intervention: MISP-NZ intervention (25 months duration) including training in recognition of suicide risk factors, workshops on mental health issues, community-based interventions, and distribution of print material and web-based resources.
Number of subjects: 8
Study 29338723 — intervention group
Group type: COMPARATOR
Intervention: Practice as usual (control group)
Number of subjects: 8
Study 26762175 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS group (mini-midvastus approach)
Number of subjects: 69
Study 26762175 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (medial parapatellar approach)
Number of subjects: 69
Study 24449012 — intervention group
Group type: COMPARATOR
Intervention: Eyes Open
Number of subjects: 0
Study 24449012 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes Closed
Number of subjects: 0
Study 24449012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically Oscillating Radial Flow
Number of subjects: 0
Study 24449012 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth Radial Flow
Number of subjects: 0
Study 24449012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating Displays
Number of subjects: 0
Study 22285969 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI
Number of subjects: 156
Study 22285969 — intervention group
Group type: COMPARATOR
Intervention: CPVI+RL
Number of subjects: 156
Study 22285969 — intervention group
Group type: COMPARATOR
Intervention: CPVI+PostBox
Number of subjects: 156
Study 21053789 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated dementia intervention (cognitive stimulation training, exercise, music, art, and horticultural therapy)
Number of subjects: 38
Study 21053789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 38
Study 17701157 — intervention group
Group type: EXPERIMENTAL
Intervention: Total oestradiol (highest vs lowest quintile)
Number of subjects: 718
Study 17701157 — intervention group
Group type: EXPERIMENTAL
Intervention: Free oestradiol (highest vs lowest quintile)
Number of subjects: 718
Study 17701157 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone (highest vs lowest quintile)
Number of subjects: 718
Study 17701157 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone (highest vs lowest quintile)
Number of subjects: 718
Study 15480814 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day (escalating to 10 mg after 1 month) and vitamin E 1,000 IU/day
Number of subjects: 104
Study 15480814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 12078939 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tapering prednisolone (40 mg/day for 8 days)
Number of subjects: 26
Study 12078939 — intervention group
Group type: COMPARATOR
Intervention: Tapering prednisolone (40 mg tapering by 5 mg/day for 8 days)
Number of subjects: 26
Study 9698776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual propranolol (40 mg)
Number of subjects: 14
Study 9698776 — intervention group
Group type: COMPARATOR
Intervention: Peroral propranolol (40 mg)
Number of subjects: 14
Study 7608665 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (mean dose 3.4 mg, range 0.8-6.0 mg)
Number of subjects: 22
Study 7608665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2930672 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 1.5%
Number of subjects: 6
Study 2930672 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (Control)
Number of subjects: 6
Study 326433 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (800 microng intranasally for 1 week)
Number of subjects: 18
Study 326433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31253718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 3994
Study 31253718 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3994
Study 30629187 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in HIV-infected adults
Number of subjects: 389
Study 28212353 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g PGX granules (PGXG)
Number of subjects: 118
Study 26306332 — intervention group
Group type: EXPERIMENTAL
Intervention: Florfenicol at 10 mg/kg (medicated feed)
Number of subjects: 30
Study 26306332 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated feed (0 mg/kg)
Number of subjects: 30
Study 23899886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hearing aid or sound generator with betahistine dihydrochloride (2HCl)
Number of subjects: 21
Study 23899886 — intervention group
Group type: COMPARATOR
Intervention: Betahistine dihydrochloride (2HCl)
Number of subjects: 21
Study 21826593 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 plus Yiqi zhuyu decoction (YZD)
Number of subjects: 120
Study 21826593 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-4 plus placebo
Number of subjects: 120
Study 19295645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g) + Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Number of subjects: 64
Study 19295645 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole (2 g) + Placebo
Number of subjects: 64
Study 16960024 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-style meals for 6 months
Number of subjects: 178
Study 16960024 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-style meals
Number of subjects: 178
Study 16960024 — intervention group
Group type: COMPARATOR
Intervention: Usual individual preplating services
Number of subjects: 178
Study 15289281 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement interventions aimed at increasing guideline‐concordant depression care
Number of subjects: 1356
Study 11208725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 50 microg
Number of subjects: 68
Study 11208725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 500 microg
Number of subjects: 68
Study 11208725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 50 microg bolus followed by continuous infusion of 50 microg/h
Number of subjects: 68
Study 11208725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 250 microg/h continuous infusion
Number of subjects: 68
Study 11208725 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated 50 microg injections of octreotide after an initial bolus
Number of subjects: 68
Study 11208725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11208725 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus and continuous octreotide infusion (50 microg/h)
Number of subjects: 68
Study 9782912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing diagnosis course (experimental group)
Number of subjects: 37
Study 9782912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nursing diagnosis course)
Number of subjects: 37
Study 7929833 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion during fasting (n = 6)
Number of subjects: 14
Study 7929833 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion during euglycemic insulin clamp (n = 8)
Number of subjects: 14
Study 7929833 — intervention group
Group type: COMPARATOR
Intervention: Control forearm during euglycemic insulin clamp
Number of subjects: 14
Study 7929833 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion in one forearm during euglycemic insulin clamp
Number of subjects: 14
Study 3129445 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.08 mg/kg BW, iv)
Number of subjects: 17
Study 3129445 — intervention group
Group type: COMPARATOR
Intervention: GnRH (50 micrograms, iv)
Number of subjects: 17
Study 3129445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31891330 — intervention group
Group type: EXPERIMENTAL
Intervention: Steno REACH Certificate Course in Clinical Diabetes Care (SRCC)
Number of subjects: 39
Study 31891330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 30297240 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy regimens (folinic acid, fluorouracil, and oxaliplatin or fluorouracil, leucovorin, and irinotecan, with or without cetuximab)
Number of subjects: 1543
Study 28396887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) placed under a coronally advanced flap (CAF)
Number of subjects: 12
Study 28396887 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG) placed under a coronally advanced flap (CAF)
Number of subjects: 12
Study 26269371 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention emphasizing spices and herbs (n = 20)
Number of subjects: 40
Study 26269371 — intervention group
Group type: COMPARATOR
Intervention: Self-directed control group (n = 20)
Number of subjects: 40
Study 24339703 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI)
Number of subjects: 0
Study 24339703 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 20370961 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 0
Study 20370961 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 0
Study 20370961 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (SGA)
Number of subjects: 0
Study 20370961 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (SGA)
Number of subjects: 0
Study 19057823 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP/Hib-BM
Number of subjects: 1000
Study 19057823 — intervention group
Group type: COMPARATOR
Intervention: DTP/Hib-GSK
Number of subjects: 1000
Study 16844625 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of TNF‐alpha rose more than 20 pg/mL during and after standard CPB in 13 patients (group 1)
Number of subjects: 20
Study 16844625 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of TNF‐alpha were less than 20 pg/mL in the remaining 7 patients (group 2)
Number of subjects: 20
Study 12727963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH (Genotropin 0.4 mg/d) for 8 months
Number of subjects: 24
Study 12727963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10969256 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin (BTA) injection plus occupational therapy
Number of subjects: 30
Study 10969256 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy alone
Number of subjects: 30
Study 8853138 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary splinting
Number of subjects: 22
Study 8853138 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 2003499 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication profile review by a clinical pharmacist
Number of subjects: 572
Study 2003499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication profile review)
Number of subjects: 572
Study 6385355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2 per cent
Number of subjects: 12
Study 6385355 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1 per cent
Number of subjects: 12
Study 6385355 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine 3 per cent plus adrenaline 0.5 per cent
Number of subjects: 12
Study 6385355 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.25 per cent
Number of subjects: 12
Study 31587950 — intervention group
Group type: COMPARATOR
Intervention: Conventional microcatheter PAE (cPAE)
Number of subjects: 89
Study 31587950 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occlusion prostatic artery embolization (bPAE)
Number of subjects: 89
Study 30249191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo-education
Number of subjects: 100
Study 30249191 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Group (ACG)
Number of subjects: 100
Study 26657482 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray application of fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Number of subjects: 21
Study 26657482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab application of fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Number of subjects: 21